



HELLENIC DYNAMICS PLC

**THIS PRESENTATION IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.**

- This presentation ("Presentation") is being provided to you by Hellenic Dynamics ("Hellenic" or the "Company") for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company. The content of this Presentation has not been approved by an authorised person for the purposes of Section 21(2)(b) of the Financial Services and Markets Act 2000. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
- This Presentation is not a prospectus or an admission document or an advertisement and should not be relied upon or treated as such. This Presentation is for the confidential use of only those persons to whom it is distributed and is not to be reproduced, distributed or used for any other purposes. No advice has been sought on any legal or taxation matter relating to the information set out in this Presentation and nothing in this Presentation constitutes investment, tax, legal or other advice. Recipients should seek their own legal, tax and financial advice in connection with the information contained herein.
- By receiving this Presentation, each recipient agrees to treat this Presentation as strictly confidential and not to reproduce, distribute or otherwise use this Presentation or any of its contents without the prior written consent of Hellenic.
- An investment in Hellenic, whether present or future, will place investor capital at risk and an investor may not get back the full amount invested. Neither past performance nor any forward-looking statements should be considered a reliable indicator of future results.
- This Presentation has been prepared for investment professionals for information and discussion purposes only and has not been approved for any other purpose. If you forward this Presentation to any other person, you must ensure that you have taken responsibility for it under applicable financial promotion rules. The information contained herein is in summary form, subject to change, and has been set out for illustrative purposes only and no reliance should be placed for any purpose on the information or opinions contained in this Presentation or their accuracy or completeness.
- The Presentation contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. The Presentation contains information of a preliminary nature that is based on unaudited information. Any proposals contained herein are subject to internal approvals, due diligence and documentation. This Presentation contains unaudited information and information from third party sources. Whilst care has been taken in compiling the content of this Presentation, the information and opinions contained in this Presentation are for background purposes only and do not purport to be full or complete. No reliance may be placed for any purpose on the information or opinions contained in this Presentation. This Presentation is not intended to provide the basis for any decision in respect of the Company whatsoever. Nothing in this Presentation forms the basis of or may be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever. No representation or warranty, express or implied, is made by Hellenic as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. This Presentation should not be copied, reproduced, divulged or distributed, in whole or in part, without the express written consent of Hellenic.
- All information contained herein is subject to updating, revision and/ or amendment (although there shall be no obligation to do so). Whilst the Company reasonably believes that the facts stated in this Presentation are accurate and that any forecasts, opinions and expectations contained therein are fair and reasonable, no representation or warranty, express or implied, is made to the fairness, accuracy, completeness or correctness of these materials or opinions contained therein and each recipient of this presentation must make its own investigation and assessment of the matters contained therein. In particular, but without prejudice to the generality of the foregoing, no representation or warranty is given, and no responsibility or liability is accepted, as to the achievement or reasonableness of any future projections or the assumptions underlying them, or any forecasts, estimates, or statements as to prospects contained or referred to in this presentation.
- This Presentation contains certain forward-looking statements. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks", or "should" or variations thereof, or by discussions of strategy, plans, objectives goals, future events or intentions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward-looking statements.
- All statements of opinion or belief contained in this Presentation and any forward-looking statements represent Hellenic's own assessment and interpretation of information available to it as at the date of this presentation. No representation is made, or assurances are given that such statements or views are correct or that the objectives of Hellenic will be achieved. Prospective investors must determine for themselves what reliance (if any) they should place on such statements, views or forecasts, and no responsibility is accepted by Hellenic in respect thereof.
- No representation is made, assurance is given, or reliance may be placed, in any respect, that such information is correct and no responsibility is accepted by Hellenic or any of its officers, agents or advisers as to the accuracy, sufficiency or completeness of any of the information or opinions, or for any errors, omissions or misstatements, negligent or otherwise, contained in or excluded from this Presentation or for any direct, indirect or consequential loss or damage suffered or incurred by any person in connection with the information contained herein save to the extent that such liability arises out of fraud or fraudulent misrepresentation.
- Nothing contained herein constitutes either an offer to sell, or the solicitation of an offer to acquire or subscribe for, shares or other securities or to enter into any agreement or arrangement in relation to matters discussed in this Presentation. Nothing herein should be taken as a financial opinion or recommendation on the part of Hellenic to enter into any transaction.
- This Presentation is not for release, publication or distribution, directly or indirectly, in whole or in part in any jurisdiction where such release, publication or distribution would be unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on Hellenic. Persons into whose possession this Presentation comes must inform themselves about, and observe, any such restrictions as any failure to comply with such restrictions may constitute a violation of the securities law of any such jurisdiction.
- This Presentation has not been approved for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA"). This Presentation is being issued to and directed only at: (i) overseas persons within the meaning of Article 12 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order"); or (ii) any other persons to whom this Presentation for the purposes of Section 21 of FSMA can otherwise lawfully be made without further action; or (iii) persons otherwise permitted by the laws of the jurisdiction in which they are resident to receive it; This Presentation is not intended to be, and must not be, distributed, passed on or disclosed, directly or indirectly, to any other class of person. This Presentation is only directed at persons outside the United Kingdom, and must not be acted upon by any persons in the United Kingdom. It is a condition of you viewing this Presentation that you fall within one of the categories of persons described above and by viewing this Presentation you will be taken to have warranted, represented and undertaken to Hellenic that: (a) you fall within one of the categories of persons described above, (b) you have read, agree to and will comply with the terms of this disclaimer; and (c) you will conduct your own analyses or other verification of the data set out in this Presentation and will bear the responsibility for all or any costs incurred in doing so. Persons who do not fall within one of the categories of persons described above should not view nor rely on this Presentation nor take any action upon it, but should immediately cease viewing of this Presentation.
- If there is any aspect of this Presentation that you do not understand, you should see advice from an appropriately authorised financial adviser.
- You are reminded that you have received this Presentation on the basis that you are a person into whose possession it may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not nor are you authorised to deliver this Presentation, electronically or otherwise, to any other person. This Presentation has been made available to you in an electronic form. You are reminded that materials transmitted via this medium may be altered or changed during the process of electronic transmission and consequently neither the Company nor any of its respective affiliates accepts any liability or responsibility whatsoever in respect of any difference between the Presentation distributed to you in electronic format and the original version. By accessing the Presentation, you consent to receiving it in electronic form.
- No responsibility or liability whatsoever is accepted by any person for any loss howsoever arising from any use of, or in connection with, this document or their contents or otherwise arising in connection therewith. In making this Presentation, Hellenic undertakes no obligation to update or to correct any inaccuracies which may become apparent in this Presentation.

HD

Transforming  
healthcare through  
THC dominant  
plant-based  
medicines





- 01 The only medical cannabis cultivator listed on the London Stock Exchange's main market, gaining Admission on 5<sup>th</sup> December 2022
- 02 Operating from a 195,506 square metre facility in northern Greece, with one of the most competitive costs of production in Europe
- 03 Cultivating in fully indoor, climate controlled, purpose-built buildings
- 04 Issued one of the largest THC licenses in Europe covering 40,000 square metres which is capable of producing over 54,000 kg per annum of medical cannabis flowers
- 05 Signed two off-take MoU's and one POD MoU representing over 4 years of phased production
- 06 Pioneering the Intersection of Medical Cannabis and biotechnology

- 01 26 countries in Europe allow medical cannabis by prescription
- 02 Market expected to reach \$17.39 billion per by 2028
- 03 European unmet demand for THC dominant medical cannabis
- 04 Near to half a million patients using medical cannabis via prescription across Europe, with numbers continuing to rise
- 05 1.5% of the UK population takes illegal cannabis for health reasons
- 06 The UK has the highest consumption rate of prescription opioid for pain management per capita in the world, with over 500k patients with dependency issues

# The Market

Opiate-related drug poisoning deaths in the UK have increased by 388% since 1993

Medical cannabis provides an alternative to prescription opioids for pain management

HD





# Medical Cannabis Treatment

available in 26  
European  
countries via  
prescription  
for...

Chronic pain  
Spinal cord treatment  
Anxiety  
HIV/AIDS appetite loss  
Multiple Sclerosis  
Crohn's disease  
PTSD  
Chemotherapy side effects

Glaucoma  
Anorexia  
Lennox-Gastaut syndrome  
Alzheimer's  
Dravet syndrome  
Tourette's syndrome  
Intractable spasticity  
Cachexia

+ more...


HD

# State of the art Greek Facility

One of Europe's  
largest facilities  
located in northern  
Greece aiming to  
be the Europe wide  
dominant  
wholesale  
cultivator of  
medical cannabis

A presentation of the Hellenic facility is  
available on the Company's website

- 01 **Facility**  
14 existing buildings on a 195k square metre facility
- 02 **Cultivation**  
Overground bunkers occupying 1,000 square metres
- 03 **Distribution**  
Located only 48 miles from the airport with daily flights to all target markets
- 04 **Production**  
One of the most competitive costs of power and labour in Europe
- 05 **License**  
40k square metre cultivation license, ample room to expand
- 06 **Location**  
Thessaloniki is Greece's second largest city with a significant pool of skilled labour



- |  |                                |
|--|--------------------------------|
| 01 Entrance, car trap & security clearance | 11 Second power substation     |
| 02 Office & security                       | 12 Propagation Bunker          |
| 03 Security HQ & storage                   | 13 P2 cultivation bunker       |
| 04 Post harvest area                       | 14 P2 cultivation bunker       |
| 05 Main power substation                   | 15 P2 cultivation bunker       |
| 06 Back-up power generator                 | 16 Main cultivation bunker     |
| 07 Water pump & tank                       | 17 Proposed POD buildings      |
| 08 Storage                                 | 21 3 km perimeter fencing with |
| 09 Storage                                 | 84 motion sensing cameras      |
| 10 Irrigation building                     |                                |



**FLUENCE**

**PRIVA**

**ORANGE CLIMATE**

**MITSUBISHI ELECTRIC**

**POLYSCAPE**

**HIKVISION**

**REMY**

**GRENETH**



## Fully Controlled Fully Indoor

- 01 The low cost of power and labour in northern Greece will allow Hellenic to be a fully indoor cultivator
- 02 Cultivating fully indoors will allow Hellenic to have up to 6 harvests per annum
- 03 Our fully insulated over ground bunkers, each with one metre thick walls should provide ideal conditions for the cultivation of medical cannabis
- 04 Growing indoors with air showers, clean rooms, air locks and at least 16 pascals of outward pressure in every building should allow Hellenic to cultivate a fully medical cannabis flower product, without the need of irradiation
- 05 Indoor cultivation should ensure the full genetic potential of the Hellenic strains are achieved, thus providing higher yields and higher total cannabinoid content
- 06 Growing indoors with well insulated buildings, Hellenic is not affected by weather nor costs associated with seasonal changes in temperature
- 07 Using state of the art LED lightening technology, with no natural sunlight, should allow Hellenic to ensure final product specifications are consistently met

	Outdoor	Glass house	Indoor
Suitable for medical purposes	No	Yes	Yes
Number of Harvests per Annum		3	6
Control of microbiology		No	Yes
Control of climate		No	Yes
Control of Lighting		No	Yes
Additional costs of heating in winter		Yes	No
Additional costs of cooling during summer		Yes	No



## World Class Genetics

Hellenic Dynamics  
has partnered with  
Nine Lions  
genetics for the  
exclusive  
cultivation of THC  
dominant strains of  
medical cannabis  
in Europe

- 01 Nine Lions is a globally renowned, Canadian-based supplier of medical cannabis tissues and clones
- 02 Operating from a world Class tissue culture lab built to EU GMP and ISO Clean Room 6 specifications
- 03 With industry leading scientists and tissue culture experts, Nine Lions work with the world's best breeders and growers to supply the largest collection of leading cannabis genetics to licensed producers
- 04 The Hellenic exclusive genetics from Nine Lions are THC dominant with high levels of cannabinoids and terpenes, in line with European demand and our customers requirements



# European Union

Hellenic is the first  
and only medical  
cannabis  
cultivator to be  
grant supported by  
the European  
Union Horizon  
Europe Project

- 01 The European Commission's Funding and Tenders Portal announced in July 2023 that Hellenic had been awarded a grant through the EU Horizon Europe Project
- 02 Hellenic is the sole medical cannabis cultivator in the consortium that was awarded the Reliable Artificial Intelligence and Data Optimisation project. The overall budget for this EU Horizon project is just under EUR €9 million over a period of 36 months
- 03 The consortium consists of 29 partners from 11 countries including Kingston University, Queen Mary University of London and Fujitsu Technology Solutions. It was noted that Hellenic's application for the EU grant funding received the highest score possible
- 04 Hellenic has also applied for a number of other grants, both at Greek and wider EU level



The Greek Institute of Genetic Improvement & Phylogenetic resources



Considered one of the top ranked universities in Greece, with a full school of health sciences



Digital medical solution enabling real-time communication and collaboration



Nine Lions is one of the highly prized Canadian cannabis genetics company's



Active in the field of software development, blockchain, big data & logistics



International research institute, serving key governmental agencies & regional authorities



The pre-eminent agricultural institution in Southern Europe



Founding member

## Partners

Supported by partners covering all aspects of the cannabis value chain including cultivation, research and development and clinical trials

- 01 Any licensed distributor or biotech company to have their own dedicated cultivation space on the Hellenic facility for the production of medical cannabis flowers
- 02 All cultivation will be handled by the experienced Hellenic team as requirements
- 03 The long-term sale of Hellenic products, specific to our clients' requirements for life of each POD agreement
- 04 Construction and equipment installation will be funded by Hellenic by way of loans, against POD agreements
- 05 White label cultivation allowing Hellenic to be the wholesale cultivator of choice, with ample area for POD operations
- 06 Each POD to be contracted for a minimum 2+2 years and capable of producing 400 kg to 1,200 kg per annum, based on agreements
- 07 An industry first in Europe, with PODs ranging to 1,500 square metres each
- 08 First POD MoU signed with Demecan – Germany's only full-service medical cannabis company to cover production of over 1,200 kg per annum

# Product Outsourcing Development

The unique Hellenic POD cultivation strategy allows

HD




# To GMP or not to GMP


## Cannabis 1.0 model required cultivators to achieve full GMP certification

- 01 GACP certification is a prerequisite for any cultivator covering all cultivation areas, this is a low capex and opex certification with low annual costs
- 02 Distributors would buy GMP products for onward sales to pharmacists

## Cannabis 2.0 model is focused on the distributor GMP certification

- 01 GMP compliance rather than full certification provides a cultivator with all requirements for sale devoid of heavy costs
- 02 Distributors have across our target markets invested in GMP certified facilities and looking to purchase GACP certified and GMP compliant products





## Pioneering the Intersection between medical cannabis and Biotech

- 01 Medical cannabis in all 26 European countries is currently limited to the prescription of flowers, oils, tinctures and vapes
- 02 Many Biotechnology companies are nearing the completion of clinical trials on cannabis plant-based medicines
- 03 Hellenic will bridge the divide by supplying medical cannabis flowers whilst also working with leading biotech companies to be the wholesale supplier of raw flowers to the pharmaceutical industry

- 01 Leveraging the unique agreement with Elgo Dimitra, the public body under the Greek Ministry of Agriculture, Hellenic has the ability to register and IP protect cannabis genetics
- 02 Hellenic is in advanced discussions with a number of biotech companies all with cannabis-based molecules in clinical trials, to provide pharmaceutical end products which are intended to be farmed out to big pharma
- 03 Hellenic's partnership with Patras University allows any biotech company working with Hellenic additional assistance in clinical trials on unique cannabis-based molecules
- 04 By providing THC dominant fully indoor grown medical cannabis to our customers, in addition to working with biotech companies, Hellenic will be in a position to bridge the gap between medical cannabis sales and wholesale production to big pharma

## Sustainable Power

- 01 Our location allows us to benefit from the surrounding solar farms, which have an over production of power
- 02 Hellenic is in advanced discussions with a number of battery producers to store the excess solar power directly at the Hellenic facility
- 03 The storage and usage of this excess power at the Hellenic facility will not only lower our energy costs, but also allow Hellenic, in time, to be one of the only carbon neutral indoor cultivator of wholesale medical cannabis

## Community

- 01 Hellenic supports its local community with investment into local education
- 02 We support biodiverse and STEM teaching in primary and secondary schools in our region
- 03 To aid our mission for improved education, we have supported schools in our local area with the supply of laptops for students to aid learning

## Corporate Social Responsibility

We are proud to look beyond the traditional borders of a company, to measure and manage our impacts on the environment and to produce a positive benefit to society

HD



**Sir Anthony Jolliffe**  
**Chairman**



**Davinder Rai**  
**CEO**



**Philip Papadopoulos**  
**Director**



**Joseph Colliver**  
**Director**



**Panos Kalafatis**  
**COO**



**Olga Dichala**  
**Head of Cultivation**



**Carl Haffner**  
**Head of Operations**



**Ricardo Arbeleda**  
**Cultivation Director**



**Amit Parhar**  
**Financial Operations**



**Anisa Bellou**  
**Administration Manager**

## The Hellenic Dynamics Team

An experienced and  
diverse team with  
significant cultivation  
and public markets  
experience, based  
between the UK and  
Greece

Full team details can be found at the Company's website

**HD**



# Advisory Board

The Hellenic team is supported by a world leading advisory board, covering all medical cannabis related legislation, sales and promotion of products and Greek support




Katherine Fleming  
Advisor



Peter Homberg  
Advisor



Michael Bennett  
Advisor



TBA  
Advisor

Full Advisory Board details can be found at the Company's website

HD



# Contact Us



21 Arlington Street  
London  
SW1A 1RN  
+44 (0) 203 818 7850  
[info@hellenicdynamics.com](mailto:info@hellenicdynamics.com)



Advisor  
Cairn Financial Advisors  
80 Cheapside  
London  
EC2V 6DZ  
Jo Turner  
[jo.turner@cairnfin.com](mailto:jo.turner@cairnfin.com)  
+44 (0) 207 213 0880



Broker  
Peterhouse Capital  
80 Cheapside  
London  
EC2V 6DZ  
Charles Goodfellow  
[cg@peterhousecap.com](mailto:cg@peterhousecap.com)  
+44 (0) 207 496 0930

